Cannabinoids for the Treatment of Dermatologic Conditions

Sivesind, Torunn; Maghfour, Jalal; Rietcheck, Hope R; Kamel, Kevin; Malik, Aaqib; Dellavalle, Robert P.

doi:10.1016/j.xjidi.2022.100095

Cited by 19 publications

(30 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study reported that the topical application of an emollient cream containing N-palmitoyl ethanolamine (PEA), a cannabinoid receptor CB2 agonist, reduced itch on average by 86.4% in patients with refractory, chronic pruritus of various etiologies [11,24] ; another open-label study evaluated PEA-containing cream in atopic dermatitis patients and reported decreased pruritus with a tolerance of 92% [25] . Since then, there have been several new formulations of topical cannabinoid oils for itch, including endocannabinoids such as anandamide, phytocannabinoids, and synthetic cannabinoids [26,27] . Xerosis is also reported to be reduced in 81% of patients [28] .…”

Section: Cannabinoidsmentioning

confidence: 99%

Therapeutics in chronic pruritus of unknown origin

Labib

Does

et al. 2023

Itch

View full text Add to dashboard Cite

Chronic pruritus of unknown origin (CPUO) is a common condition that is underrecognized and underdiagnosed. Patients suffer from 6 or more weeks of pruritus with no identified cause, or with multiple potential causes, of which the primary cause cannot be determined. Despite being a common condition and prevalent in nearly 30% of the elderly in certain populations, most patients suffer from CPUO for years from inadequate treatments for itch and are made to undergo extensive diagnostics. There is no FDA-approved treatment for CPUO, and providers are often tasked to treat CPUO patients with limited knowledge and guidance on CPUO and its treatments. However, recent breakthroughs in antipruritic therapeutics have led to an increase in therapies available for CPUO patients. These include a variety of both pharmacological and nonpharmacological interventions, as well as topical and systemic therapies. Newer therapies such as biologics and Janus kinase inhibitors are currently under investigation due to their therapeutic effects in other pruritic diseases and are promising for treating CPUO. Here, we review the various therapeutic options that are currently available or are on the horizon, with a special emphasis on the therapies antipruritic mechanism, available clinical evidence of efficacy and safety, and the appropriate contexts for their application. By doing so, we hope to educate clinicians on the known treatments for pruritus and their applicability to CPUO to guide optimal management of this highly prevalent disease.

show abstract

Section: Cannabinoidsmentioning

confidence: 99%

Therapeutics in chronic pruritus of unknown origin

Labib

Does

et al. 2023

Itch

View full text Add to dashboard Cite

show abstract

“…Structurally, THC and CBD are classical cannabinoids [71]. Phytocannabinoids and their receptors are summarized in Table 3.…”

Section: Phytocannabinoidsmentioning

confidence: 99%

Cannabinoids And Cannabinoid-Like Compounds: Biochemical Characterization And Pharmacological Perspectives

et al. 2023

View full text Add to dashboard Cite

Publication interest in cannabinoids, including phytocannabinoids, endogenous cannabinoids, synthetic cannabinoids and cannabinomimetic compounds, is due to the therapeutic potential of these compounds in inflammatory pathology. Since recent years, scientific interest was focused on compounds with cannabinomimetic activity. The therapeutic use of phytocannabinoids and endocannabinoids is somewhat limited due to unresolved issues of dosing, toxicity and safety in humans, while cannabinoid-like compounds combine similar therapeutic effects with a high confirmed safety. Targets for endocannabinoids and phytocannabinoids are endocannabinoid receptors 1 and 2, G protein-coupled receptors (GPCRs), peroxisome proliferator-activated receptors (PPARs), and transient receptor potential ion channels (TRPs). Non-endocannabinoid N-acylethanolamines do not interact with cannabinoid receptors and exhibit agonist activity towards non-cannabinoid receptors, such as PPARs, GPCRs and TRPs. This literature review includes contemporary information on the biological activity, metabolism and pharmacological properties of cannabinoids and cannabinoid-like compounds, as well as their receptors. We established that only a few studies were devoted to the relationship of non-endocannabinoid N-acylethanolamines with non-cannabinoid receptors, such as PPARs, GPCRs, and also with TRPs. We have focused on issues that were insufficiently covered in the published sources in order to identify gaps in existing knowledge and determine the prospects for scientific research.

show abstract

“…15,16 The phytocannabinoid family includes over 100 compounds, among which delta-9-tetrahydrocannabinol [Δ 9 -THC] and cannabidiol [CBD] are the most notable. 16 16 Synthetic cannabinoids were first synthesized in the 20th century-dronabinol and nabilone are two prominent examples. 16 The FDA approved these two compounds for treating acquired immunodeficiency syndrome-induced anorexia and chemotherapy-induced nausea and vomiting.…”

Section: S E Arch S Tr Ategy and Me Thodmentioning

confidence: 99%

“…The phytocannabinoid family includes over 100 compounds, among which delta‐9‐tetrahydrocannabinol [Δ 9 ‐THC] and cannabidiol [CBD] are the most notable 16 . Anandamide [AEA], 2‐arachidonoylglycerol [2‐AG], and the endogenous fatty acid amide N‐palmitoylethanolamide [N‐PEA] are the three most important and clinically relevant endocannabinoids 16 . Synthetic cannabinoids were first synthesized in the 20th century—dronabinol and nabilone are two prominent examples 16 .…”

Section: Classification Of Cannabinoidsmentioning

confidence: 99%

See 1 more Smart Citation

A cannabinoid Hairy‐Tale: Hair loss or hair gain?

Gupta

Talukder

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Few studies have reported on the use of cannabinoid products to treat hair loss. Aim This article aims to reconcile cannabinoids' impact on hair growth. Method A comprehensive and structured search was conducted in PubMed and Google Scholar on June 23, 2022. Result While cannabidiol (CBD), a phytocannabinoid, may cause hair growth, several other phytocannabinoids may lead to hair loss. Additionally, the effect of CBD on hair growth may be concentration‐dependent. CBD may cause hair loss at high concentrations (≥10 μM). Therefore, the concentration of CBD needs to be adjusted so that it is optimal for hair growth. One trial found that once‐daily application of CBD‐rich topical cannabis extract for 6 months increased nonvellus hair count by approximately 93.5% in 35 Caucasian AGA patients: 28 males aged 28–72 years [average 43 years] and 7 females aged 46–76 years [average 61 years]. Each application contained 3–4 mg of CBD. The CBD‐rich topical cannabis extract was prepared by ultra‐pulverizing Cannabis sativa [hemp] flower into a green chalk‐like powder [10.78% CBD and 0.21% tetrahydrocannabinol] and then infusing the powder into a lanolin paste and Emu oil carrier. Conclusion Topical CBD preparations require further studies to establish their safety and efficacy profile. An ideal topical cannabinoid preparation should contain CBD at the right concentration and lack other phytocannabinoid adulterants.

show abstract

Cannabinoids for the Treatment of Dermatologic Conditions

Cited by 19 publications

References 39 publications

Therapeutics in chronic pruritus of unknown origin

Therapeutics in chronic pruritus of unknown origin

Cannabinoids And Cannabinoid-Like Compounds: Biochemical Characterization And Pharmacological Perspectives

A cannabinoid Hairy‐Tale: Hair loss or hair gain?

Contact Info

Product

Resources

About